Solifenacin Succinate (HCID 216457)

이름 및 식별자

우선 이름: Solifenacin Succinate
IUPAC: [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid
영어명: Solifenacin succinate
분자식: C27H32N2O6
분자량: 480.56

이름 및 동의어

Solifenacin succinate242478-38-2VesicareYM905YM 905KKA5DLD701YM-905YM67905YM-67905VESICARE LSsolifenacin succiatesolifenacine succinate

이름 더 보기

CS-353VesikurYM 67905Solfenacin42478-38-2IsoprenalinoeSulfateSolefinacin SuccinateSophenazine succinate

Succinate, SolifenacinRefChem:6251solifenacin succinate 5 mgsolifenacin succinate 10 mgSolifenacin Succinate Tablets905, YMquinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinateSolifenacin succinate [USAN]

데이터베이스 식별자

CAS: 242478-38-2
PubChem CID: 216457
DTXSID: DTXSID30947075
ChEMBL: CHEMBL1200803
ChEBI: CHEBI:32151
UNII: KKA5DLD701
EC Number: 620-505-5

물성

구조 계산 물성

극성 표면적: 107 Å²
수소 결합 공여자 수: 2
수소 결합 수용자 수: 7
회전 가능 결합 수: 6
무거운 원자 수: 35
형식 전하: 0
복잡도: 617

실험 및 물리화학적 성질

Collision Cross Section201 Å² [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점: 145 ° · ~145°
저장 조건: 2 · under inert gas (nitrogen or Argon) at 2-8°C
용해도: 메탄올(약간 용해됨,가열, 초음파 처리), 물(약간 용해됨,초음파 처리)
물리적 상태: 고체
색상: 흰색에서 황백색까지
수용성: 2 O: · H2O: 2mg/mL, clear
Merck: 14 · 14,8712
안정성: 흡습성
InChIKey: RXZMMZZRUPYENV-ZFHAYXBFNA-N
SMILES: C(C(=O)O)CC(=O)O.C(N1CCC2=CC=CC=C2[C@@H]1C1C=CC=CC=1)(=O)O[C@H]1CN2CCC1CC2 |&1:18,27,r|

화학적 성질

White Solid

안전 및 규제

GHS 분류

GHS Classification · 5건

Warning

H302 (92.8%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 69 reports by companies from 12 notifications to the ECHA C&L Inventory.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (92.8%)

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Solifenacin succinate

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 1건

◉ Summary of Use during Lactation；Because there is no published experience with solifenacin during breastfeeding and it has a long half-life averaging 55 hours, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Long-term use of solifenacin might reduce milk production or milk letdown. During long-term use, observe the infant for signs of decreased milk production (e.g., insatiety, poor weight gain) and for anticholinergic symptoms (e.g., constipation, urinary retention, UTI, dry mouth).；◉ Effects in Breastfed Infants；Relevant published information was not found as of the revision date.；◉ Effects on Lactation and Breastmilk；Anticholinergics can inhibit lactation in animals, apparently by inhibiting growth hormone and oxytocin secretion. Anticholinergic drugs can also reduce serum prolactin in nonnursing women. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

안전 데이터

wgk: WGK 3
rtecs: NW7136000
HS 번호: 29339900
Hazard Classifications: Repr. 2
스토리지 클래스: 11 - Combustible Solids

화학 및 산업

약리 정보

FDA Pharmacological Classification · 6건

SOLIFENACIN SUCCIATE

Cholinergic Muscarinic Antagonist [EPC]; Cholinergic Muscarinic Antagonists [MoA]

SOLIFENACIN SUCCINATE

Cholinergic Muscarinic Antagonist [EPC]; Cholinergic Muscarinic Antagonists [MoA]

SOLIFENACIN SUCCINATE TABLETS

Cholinergic Muscarinic Antagonists [MoA]; Cholinergic Muscarinic Antagonist [EPC]

MeSH Pharmacological Classification · 2건

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

응용 분야 · 2건

용도Solifenacin succinate is a urinary antispasmodic of the antimuscarinic class.

일반 설명Solifenacin succinate (Vesicare),(+)-(1S, 3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate, is a competative antagonistfor M1, M2, and M3 receptor subtypes. One of the issues surroundingthe use of such antagonists is the selectivity for thebladder over other tissue such as the salivary glands. It isreported that the selectivity of solifenacin for bladder muscarinicreceptors over salivary receptors is superior to theeffects observed with oxybutynin.